New Staging System for HPV-positive Oropharyngeal Cancer Proposed

Share this content:
The ICON-S developed a TNM classification specific to human papillomavirus (HPV)-related oropharyngeal cancer.
The ICON-S developed a TNM classification specific to human papillomavirus (HPV)-related oropharyngeal cancer.

The International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S) developed a TNM classification specific to human papillomavirus (HPV)-related oropharyngeal cancer.1

The proposed model is suitable for the 8th edition of the Union for International Cancer Control/American Joint Committee on Cancer TNM classification although more study is needed to determine whether T and N categories should be further refined.

 

Researchers sought to develop a TNM classification specific to HPV-positive oropharyngeal cancer because many prognostic algorithms use HPV status as a stratification factor, ignoring the uniqueness of HPV-positive cancers.

A total of 1907 patients with HPV-positive oropharyngeal cancer from 7 cancer centers across Europe and North American were included in the study. One center served as the training cohort (661 patients; 35%) and 6 were in the validation cohorts (1246 patients; 65%).

Overall survival at 5 years was compared between the training and validation cohorts. Recursive partitioning analysis and adjusted hazard ratio modeling methods were used to derive new staging classifications.

Results showed that 5-year overall survival was similar for 7th edition TNM stage 1, 2, 3, and 4a (respectively; 88% [95% CI, 74 - 100]; 82% [71 - 95]; 84% [79 - 89]; and 81% [79 - 83]; global P = .25) but was lower for stage 4b (60% [53 - 68]; P < .0001).

Five-year overall survival did not differ among NO, N1-N2a, and N2b subsets, but was significantly lower for patients with N3 disease. The N categories were re-termed: ICON-S NO, no lymph nodes; ICON-S N1, ipsilateral lymph nodes; ICON-S N2, bilateral or contralateral lymph nodes; and ICON-S N3, lymph nodes larger than 6 cm.

RELATED: HPV-16 in Oral Cavity Associated With Increased Risk of Oropharyngeal Squamous Cell Carcinoma

Five-year overall survival was also similar among patients classed as T4a and T4b, therefore investigators no longer subdivided T4 in the re-termed ICON-S T categories. The proposed ICON-S classification is stage 1 (T1-T2N0-N1), stage 2 (T1-T2N2 or T3N0-N2), and stage 3 (T4 or N3); stage 4 (metastatic disease).

Reference

  1. O'Sullivan B, Huang SH, Su J, et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study [published online ahead of print February 26, 2016]. Lancet Oncol. doi: 10.1016/S1470-2045(15)00560-4.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters